Scott Solomon from Brigham and Women's Hospital: Building Momentum to Help Heart Failure Patients

As new medications are introduced to the market there can be some hesitation by doctors to make the jump from more traditional treatment options. Moving beyond that has shown benefits for a patient's long term health.

As new medications are introduced to the market there can be some hesitation by doctors to make the jump from more traditional treatment options. Moving beyond that has shown benefits for a patient's long term health.

One such medication being studied in this effort is sacubitril/valsartan, also known as entresto. Scott David Solomon, MD, from Brigham & Women's Hospital and Harvard Medical School discussed the results of the Paradigm-HF trial which studied how the medication can help even "stable" heart failure patients. Solomon said the results of the study showed the benefit of this medication would work when compared to other patients including those ACE inhibitors or ARBs.